17,190
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Long-term safety and efficacy of breast biopsy markers in clinical practice

, , , & ORCID Icon
Pages 121-128 | Received 08 Sep 2020, Accepted 16 Nov 2020, Published online: 07 Dec 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Elian A. Martin, Neeraj Chauhan, Vijian Dhevan, Elias George, Partha Laskar, Meena Jaggi, Subhash C. Chauhan & Murali M. Yallapu. (2022) Current status of biopsy markers for the breast in clinical settings. Expert Review of Medical Devices 19:12, pages 965-975.
Read now

Articles from other publishers (4)

Eun L. LangmanKaren S. JohnsonMaggie L. Dinome. (2023) Retained Biopsy Site Markers After Breast Lesion Surgical Resection: Associations With Residual Malignancy. American Journal of Roentgenology.
Crossref
Samantha Chen & Donna Taylor. (2022) Vanishing HydroMARK breast biopsy markers . ANZ Journal of Surgery 93:1-2, pages 344-345.
Crossref
Eman El-bakoury, Walid Mohamed Abd El Maksoud, Mohamed Hussein Sultan, Yasmine Nagy Elwany, Mohammed A. Bawahab, Yasser S. Ahmed & Ayman Ahmed Mehanna. (2022) Ultrasound-guided percutaneous insertion of small vascular surgical clips versus dedicated breast mammoclips as markers for breast cancer prior to neo-adjuvant therapy: a prospective randomized controlled trial. Egyptian Journal of Radiology and Nuclear Medicine 53:1.
Crossref
Irene L. M. Reijers, Alexander M. Menzies, Alexander C. J. van Akkooi, Judith M. Versluis, Noëlle M. J. van den Heuvel, Robyn P. M. Saw, Thomas E. Pennington, Ellen Kapiteijn, Astrid A. M. van der Veldt, Karijn P. M. Suijkerbuijk, Geke A. P. Hospers, Elisa A. Rozeman, Willem M. C. Klop, Winan J. van Houdt, Karolina Sikorska, Jos A. van der Hage, Dirk J. Grünhagen, Michel W. Wouters, Arjen J. Witkamp, Charlotte L. Zuur, Judith M. Lijnsvelt, Alejandro Torres Acosta, Lindsay G. Grijpink-Ongering, Maria Gonzalez, Katarzyna Jóźwiak, Carolien Bierman, Kerwin F. Shannon, Sydney Ch’ng, Andrew J. Colebatch, Andrew J. Spillane, John B. A. G. Haanen, Robert V. Rawson, Bart A. van de Wiel, Lonneke V. van de Poll-Franse, Richard A. Scolyer, Annelies H. Boekhout, Georgina V. Long & Christian U. Blank. (2022) Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nature Medicine 28:6, pages 1178-1188.
Crossref